196 related articles for article (PubMed ID: 31954088)
21. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
22. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J
Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720
[TBL] [Abstract][Full Text] [Related]
24. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
[TBL] [Abstract][Full Text] [Related]
25. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
[TBL] [Abstract][Full Text] [Related]
26. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
[TBL] [Abstract][Full Text] [Related]
27. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G
J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914
[TBL] [Abstract][Full Text] [Related]
29. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
[No Abstract] [Full Text] [Related]
30. Differential Profile of Primary and Recurrent Ameloblastomas Among Afro-descendants and Non-Afro-descendants-a Systematic Review.
Patel P; Effiom OA; Akinshipo AO; Akintoye SO
J Racial Ethn Health Disparities; 2024 Feb; 11(1):92-100. PubMed ID: 36596981
[TBL] [Abstract][Full Text] [Related]
31. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres.
Bonacina R; Indini A; Massazza G; Rulli E; Gianatti A; Mandalà M;
J Clin Pathol; 2022 Aug; 75(8):555-559. PubMed ID: 33827932
[TBL] [Abstract][Full Text] [Related]
32. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
[TBL] [Abstract][Full Text] [Related]
33. Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration.
Hirschhorn A; Campino GA; Vered M; Greenberg G; Yacobi R; Yahalom R; Barshack I; Toren A; Amariglio N; Rechavi G
J Tissue Eng Regen Med; 2021 Dec; 15(12):1155-1161. PubMed ID: 34599642
[TBL] [Abstract][Full Text] [Related]
34. Fluorescence in-situ hybridization identifies Mastermind-like 2 (MAML2) rearrangement in odontogenic cysts with mucous prosoplasia: a pilot study.
Argyris PP; Wehrs RN; García JJ; Koutlas IG
Histopathology; 2015 May; 66(6):791-7. PubMed ID: 25123064
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic study on a rare variant of ameloblastoma with basal cell features.
You Z; Sun L; Yan X; Zhang J; Du J; Li T; Zhao H
Oral Dis; 2019 Apr; 25(3):788-795. PubMed ID: 30561173
[TBL] [Abstract][Full Text] [Related]
36. Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis.
Cipriani NA; Lusardi JJ; McElherne J; Pearson AT; Olivas AD; Fitzpatrick C; Lingen MW; Blair EA
Am J Surg Pathol; 2019 Jul; 43(7):885-897. PubMed ID: 31021855
[TBL] [Abstract][Full Text] [Related]
37. Glandular odontogenic cysts (GOCs) lack MAML2 rearrangements: a finding to discredit the putative nature of GOC as a precursor to central mucoepidermoid carcinoma.
Bishop JA; Yonescu R; Batista D; Warnock GR; Westra WH
Head Neck Pathol; 2014; 8(3):287-90. PubMed ID: 24647913
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.
Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM
Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197
[TBL] [Abstract][Full Text] [Related]
39. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
[TBL] [Abstract][Full Text] [Related]
40. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
